bromocriptine versus cabergoline for the symtomatic treatment of cyclic mastalgia

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000543381

Enrollment

Registered

2008-10-28

Start date

2007-09-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Cabergoline will be given to intervention group at premenstrual period to decrease premenstrual breast pain.Patients will take one oral tablet cabergoline(0.5mg) at 14th day of menstruation and second oral tablet (0.5mg)at next week same day(one tablet in a week).Participants will take cabergoline for three consecutive menstrual cycles.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 44 Years

Healthy volunteers

Yes

Inclusion criteria

healthy women at reproductive age, having monthly mastalgia of moderate or severe which breast pain relieves after menstruation.

Exclusion criteria

breast Cancer,uncontrolled diabetus,hypertension or other chronic illnesses,breast operation or radiotherapy or other breast diseases

Outcome results